Alexander Salerno, MD
Internal Medicine · East Orange, NJNPI 1962476903
Payments from drug & device makers
What this record shows
This record is dominated by other: $63,080 of the $90,850 with a category attached, or 69.4%. Angiodynamics, Inc. accounts for 91.6% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $27,402, 3.6 times the $7,556 reported in 2019. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $383.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$83K
- Roche Diagnostics Corporation$3K
- Novartis$2K
- AbbVie$689
- Novo Nordisk$522
- GSK$441
- plus $1K from 21 others
What the payments were for
- Consulting fees$4,5025%
- Food & beverage$3,2454%
- Education$20,02322%
- Other$63,08069%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 23 | $83,201 |
| Roche Diagnostics Corporation | 1 | $2,750 |
| Novartis | 16 | $2,015 |
| AbbVie(2 entities) | 53 | $689 |
| Novo Nordisk | 34 | $522 |
| GSK | 33 | $441 |
| Lilly USA, LLC | 17 | $227 |
| Pfizer | 10 | $148 |
| Madrigal Pharmaceuticals | 2 | $124 |
| Boehringer Ingelheim | 8 | $121 |
| AstraZeneca | 7 | $94 |
| Bayer | 4 | $71 |
| Dexcom, Inc. | 3 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Merck | 3 | $41 |
| Amarin Pharma, Inc. | 3 | $40 |
| Gilead | 3 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Hologic Sales And Service, LLC | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Abbott | 1 | $23 |
| Amgen | 1 | $19 |
| Averitas Pharma Inc. | 1 | $16 |
| Smith+Nephew | 1 | $14 |
| Lifescan, Inc. | 1 | $14 |
| Infobionic, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaCure 1470 Pro$72,680
- EVLT$10,400
- POC cobas Liat Analyzer, Assays, Controls and Accessories$2,750
- REZDIFFRA$108
How this compares
$90,850 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QutenzaCapsaicin/Skin Cleanser | 208 | $732,611 |
| JardianceEmpagliflozin | 206 | $182,920 |
| EliquisApixaban | 216 | $156,228 |
| MounjaroTirzepatide | 123 | $140,157 |
| Repatha SureclickEvolocumab | 181 | $127,284 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 166 | $114,424 |
| EnbrelEtanercept | 13 | $103,741 |
| TrulicityDulaglutide | 85 | $96,531 |
| OzempicSemaglutide | 84 | $86,926 |
| KerendiaFinerenone | 101 | $85,683 |
| ProcritEpoetin Alfa | 20 | $55,349 |
| Praluent PenAlirocumab | 63 | $45,644 |
| EntrestoSacubitril/Valsartan | 70 | $44,500 |
| VascepaIcosapent Ethyl | 132 | $43,606 |
| FarxigaDapagliflozin Propanediol | 65 | $36,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Synjardy, Glyxambi | $121 | $283,040352 claims |
| Lilly USA, LLCMounjaro, Trulicity | $227 | $236,688208 claims |
| PfizerEliquis | $148 | $156,228216 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $441 | $134,549216 claims |
| AmgenEnbrel | $19 | $103,74113 claims |
| Novo NordiskOzempic | $522 | $86,92684 claims |
| BayerKerendia | $71 | $85,683101 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $94 | $63,719102 claims |
| NovartisEntresto | $2,015 | $44,50070 claims |
| AbbVieLinzess | $689 | $30,61541 claims |
| MerckJanuvia | $41 | $16,40818 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $44 | $7,78013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in East Orange
- Darshi SunderamEast Orange$530K
- Gnana SunderamEast Orange$33K
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.